Difference between revisions of "Comment Resolutions"
Jump to navigation
Jump to search
(Sorted by date of feedback closure) |
|||
| Line 12: | Line 12: | ||
| colspan="4" align="center" style="background:#dddddd" | '''CT Profiles''' | | colspan="4" align="center" style="background:#dddddd" | '''CT Profiles''' | ||
|- | |- | ||
| − | | [[Media: | + | | [[Media:QIBA_CT_Vol_LungNoduleAssessmentInCTScreening_v5-2-16b.docx| CT Small Lung Nodule Screening 2016-06-01]] |
| Public Comment | | Public Comment | ||
| − | | | + | | 2016.09 |
| − | | [[Media: | + | | [[Media:2018-06-15 v9 QIBA SLN CommentsAndResolutions.xlsx|Public Comment Resolutions 2018-06-15]] |
|- | |- | ||
| [[Media:QIBA_CTVol_TumorVolumeChangeProfile_Consensus-20161121b.pdf| CT Tumor Volumetry for Advanced Disease 2016-11-21b]] | | [[Media:QIBA_CTVol_TumorVolumeChangeProfile_Consensus-20161121b.pdf| CT Tumor Volumetry for Advanced Disease 2016-11-21b]] | ||
| Line 21: | Line 21: | ||
| 2017.02 | | 2017.02 | ||
| [https://docs.google.com/spreadsheets/d/1cyz0frvELb6Tq1EHjpHxnvjeUxotExnJ3OrKPdIa30U/edit?usp=sharing Technical Confirmation Resolutions 2018-02-25] | | [https://docs.google.com/spreadsheets/d/1cyz0frvELb6Tq1EHjpHxnvjeUxotExnJ3OrKPdIa30U/edit?usp=sharing Technical Confirmation Resolutions 2018-02-25] | ||
| + | |- | ||
| + | | [[Media:QIBA_CTA_Profile_as_of_2019-Feb-29.pdf| CT Atherosclerosis 2019-02-29]] | ||
| + | | Public Comment | ||
| + | | 2019.06.03 | ||
| + | | [[Media:QIBA_CTA_Comments_all resolved.xlsx| Public Comment Resolutions 2020-03-12]] | ||
|- | |- | ||
| [[Media:QIBA_CT_Vol_SmallLungNoduleAssessmentInCTScreening_2018.11.18-clean-3.pdf|CT Small Lung Nodule Screening 2018-11-18]] | | [[Media:QIBA_CT_Vol_SmallLungNoduleAssessmentInCTScreening_2018.11.18-clean-3.pdf|CT Small Lung Nodule Screening 2018-11-18]] | ||
| Line 26: | Line 31: | ||
| 2020.04 | | 2020.04 | ||
| '''Resolving Feedback''' | | '''Resolving Feedback''' | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
| colspan="4" align="center" style="background:#dddddd" | '''MR Profiles''' | | colspan="4" align="center" style="background:#dddddd" | '''MR Profiles''' | ||
|- | |- | ||
| − | | [[Media: | + | | [[Media:QIBADWIProfilev1.45_20170427_v5_accepted_linenumbers.pdf| MR DWI 2017-04-27]] |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| Public Comment | | Public Comment | ||
| − | | 2017. | + | | 2017.08.25 |
| '''Resolving Feedback''' | | '''Resolving Feedback''' | ||
|- | |- | ||
| Line 49: | Line 44: | ||
| '''Resolving Feedback''' | | '''Resolving Feedback''' | ||
|- | |- | ||
| − | | [[Media: | + | | [[Media:QIBA_fMRI_Profile_1_PC-rev1.pdf| fMRI Sensorimotor 2017-06-19]] |
| Public Comment | | Public Comment | ||
| − | | 2017. | + | | 2017.12.31 |
| '''Resolving Feedback''' | | '''Resolving Feedback''' | ||
| + | |- | ||
| + | | [[Media:QIBADWIProfile_as_of_2019-Feb-05.pdf| MR DWI 2019-02-05]] | ||
| + | | Public Comment #2 | ||
| + | | 2019.04.05 | ||
| + | | [[Media:QIBA DWI Profile-Public Comment--2 Resolutions.pdf| Public Comment Resolutions]] | ||
|- | |- | ||
| colspan="4" align="center" style="background:#dddddd" | '''PET/NM Profiles''' | | colspan="4" align="center" style="background:#dddddd" | '''PET/NM Profiles''' | ||
| + | |- | ||
| + | | SPECT Ioflupane in Neurodegenerative Disease v1.1 | ||
| + | | Public Comment | ||
| + | | 2016.12.31 | ||
| + | | [[Media: SPECT Profile Response to Public Comments.v2017 06 06.xlsx | Public Comment Resolutions 2017-06-06]] | ||
|- | |- | ||
| [[Media:QIBA_AmyloidPET_15June2017.pdf| PET Amyloid 2019-06-15]] | | [[Media:QIBA_AmyloidPET_15June2017.pdf| PET Amyloid 2019-06-15]] | ||
| Line 65: | Line 70: | ||
| n/a | | n/a | ||
| v2.0 is an update of v1.0 without additional public comment | | v2.0 is an update of v1.0 without additional public comment | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|- | |- | ||
| [[Media:QIBA_99mTC SPECT 2020-05-12.pdf| SPECT 99mTC 2020-05-12]] | | [[Media:QIBA_99mTC SPECT 2020-05-12.pdf| SPECT 99mTC 2020-05-12]] | ||
Revision as of 23:44, 7 July 2020
Comments received during Public Comment, Technical Confirmation, or during a Profile ballot, are reviewed by the originating Biomarker Committee.
Per the QIBA Process, committees record how each collected comment was resolved and those resolutions are posted here.
| Profile Document | Feedback Type | Feedback Closed | Resolutions |
|---|---|---|---|
| CT Profiles | |||
| CT Small Lung Nodule Screening 2016-06-01 | Public Comment | 2016.09 | Public Comment Resolutions 2018-06-15 |
| CT Tumor Volumetry for Advanced Disease 2016-11-21b | Technical Confirmation | 2017.02 | Technical Confirmation Resolutions 2018-02-25 |
| CT Atherosclerosis 2019-02-29 | Public Comment | 2019.06.03 | Public Comment Resolutions 2020-03-12 |
| CT Small Lung Nodule Screening 2018-11-18 | Technical Confirmation | 2020.04 | Resolving Feedback |
| MR Profiles | |||
| MR DWI 2017-04-27 | Public Comment | 2017.08.25 | Resolving Feedback |
| MR Elastography 2017-08-15 | Public Comment | 2017.09.15 | Resolving Feedback |
| fMRI Sensorimotor 2017-06-19 | Public Comment | 2017.12.31 | Resolving Feedback |
| MR DWI 2019-02-05 | Public Comment #2 | 2019.04.05 | Public Comment Resolutions |
| PET/NM Profiles | |||
| SPECT Ioflupane in Neurodegenerative Disease v1.1 | Public Comment | 2016.12.31 | Public Comment Resolutions 2017-06-06 |
| PET Amyloid 2019-06-15 | Public Comment | 2017.09.15 | Public Comment Resolutions 2018-05-02 |
| SPECT Ioflupane in Neurodegenerative Disease v2.0, 2019-10-15 | Public Comment | n/a | v2.0 is an update of v1.0 without additional public comment |
| SPECT 99mTC 2020-05-12 | Public Comment | 2020.02.03 | Public Comment Resolutions 2020-05-12 |